Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention

Table 2

The association between thrombocytopenia and the occurrence of clinical outcomes.

Clinical outcomes	With TCP ()	Without TCP ()	value	Adjusted odds ratio (95% CI)^$	value
	(%)
Primary outcome: all-cause mortality, bleeding, or transfusion	37 (4.0)	215 (2.5)	0.009	1.30 (0.88–1.93)	0.19
All-cause mortality	16 (1.7)	93 (1.1)	0.09	1.23 (0.67–2.25)	0.50
Bleeding	14 (1.5)	85 (1.0)	0.15
	12 (1.3)	51 (0.6)	0.014	1.90 (0.98–3.68)	0.06
BARC 1	2 (0.2)	34 (0.4)
BARC 2	6 (0.6)	21 (0.2)
BARC 3a	4 (0.4)	16 (0.2)
BARC 3b	1 (0.1)	9 (0.1)
BARC 3c	0 (0)	3 (0)
BARC 5a	1 (0.1)	2 (0)
Transfusion	18 (1.9)	90 (1.0)	0.016	1.53 (0.88–2.66)	0.13
RBC transfusion	16 (1.7)	79 (0.9)	0.021	1.52 (0.85–2.72)	0.16
Platelet transfusion	1 (0.1)	4 (0.05)	0.99
Plasma transfusion	4 (0.4)	18 (0.2)	0.34
Secondary outcome: MACE or CVA	28 (3.0)	212 (2.5)	0.33	1.03 (0.68–1.57)	0.89
MACE	19 (2.0)	123 (1.4)	0.15	1.14 (0.67–1.94)	0.63
Cardiac mortality	13 (1.4)	85 (1.0)	0.25	1.08 (0.56–2.06)	0.82
Myocardial infarction	3 (0.3)	29 (0.3)	1.0
Target vessel revascularization	3 (0.3)	5 (0.1)	0.042	4.93 (1.13–21.46)	0.03
Stent thrombosis	0 (0)	8 (0.1)	1.0
Ischemic CVA	9 (1.0)	93 (1.1)	0.73	0.83 (0.41–1.65)	0.59
Hemorrhagic CVA	0 (0)	3 (0)	1.0
Length of stay (days)	5 (3–7)	4 (3–6)	0.007	0.01 (-0.01–0.02)^&	0.52

PCI: percutaneous coronary intervention; TCP: thrombocytopenia; CI: confidence interval; BARC: Bleeding Academic Research Consortium; RBC: red blood cell; MACE: major adverse cardiovascular events, including in-hospital cardiac mortality, myocardial infarction, target vessel revascularization, or stent thrombosis; CVA: cerebrovascular accident. ^$Adjusted for the propensity score in regression models. ^& coefficient (95% CI) of lg10-transformed length of stay.